In a recent hearing held in Amgen v. Hospira, the parties offered arguments on some novel issues relating to litigation under the BPCIA, particularly: Whether a reference product sponsor (“RPS”) can compel a biosimilar applicant to produce manufacturing information that may be relevant to other patents it holds, but is…
IPR2016-01018 (Coherus BioSciences Inc.) (U.S. Patent No. 9,114,166) Petitioner: Coherus BioSciences Inc. Patent: U.S. Patent No. 9,114,166 Title: Formulation of human antibodies for treating TNF-α associated disorders Related Product: HUMIRA® Patent Owner: AbbVie Biotechnology Ltd.
A recent court ruling and a new publication on guidelines for biosimilars in India may offer further guidance on what biosimilar and biologic stakeholders can expect from Indian regulatory authorities. In late March, India’s Central Drugs Standard Control Organization (CDSCO) published Proposed Revised Guidelines on Similar Biologics (2016), offering guidance…
Biocon recently announced that its global phase III clinical development program for biosimilar insulin glargine “has crossed key interim milestones,” putting Biocon “on track for regulatory filings in US and EU in FY 17.” Biocon received regulatory approval in Japan for its biosimilar insulin glargine this past March after completion…
We previously reported that the FDA approved Celltrion’s Inflectra®, a biosimilar to Janssen’s Remicade® (infliximab). We also reported on a series of letters concerning Janssen’s request for an expedited trial in view of a possible Celltrion launch in October of 2016. In a letter filed with the court yesterday, Janssen…
IPR2016-00912 (Swiss Pharma Int’l AG) (U.S. Pat. No. 8,815,236) Petitioner: Swiss Pharma Int’l AG Patent: U.S. Patent No. 8,815,236 Patent Title: Method of Treating Multiple Sclerosis and Crohn’s Disease Patent Assignee: Biogen Idec MA, Inc. IPR2016-00915 (Swiss Pharma Int’l AG) (U.S. Pat. No. 8,349,321) Petitioner: Swiss Pharma Int’l AG Patent:…
Last month, the FDA released draft industry guidance on Labeling for Biosimilar Products. The draft guidance provides FDA’s labeling recommendations for applicants seeking approval to market biosimilar products and applies only to non-interchangeable product. The draft guidance describes the FDA’s expectations about what information biosimilar manufacturers should include in their labels…
We previously reported that the FDA approved Celltrion’s Inflectra®, a biosimilar to Janssen’s Remicade® (infliximab). Last week, we also reported that in Janssen v. Celltrion, Janssen filed a letter to the court stating that the “Defendants notified us that they intend to begin commercial sales of their biosimilar in no later than 180 days…
As we previously reported, AbbVie filed a citizen petition in December, asking the FDA to convene a Part 15 hearing on interchangeability determinations and to tighten the standards for that determination by, for example, requiring that all indications of the reference product be studied prior to granting an interchangeability designation,…
One week ago, we reported that FDA approved Celltrion’s Inflectra, a biosimilar to Janssen’s Remicade (infliximab). Today, Janssen filed a letter to the court in Janssen v. Celltrion informing the court that the “Defendants notified us that they intend to begin commercial sales of their biosimilar in no later than 180 days…